SAN DIEGO, Feb 08, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Vical Incorporated (Nasdaq: VICL) today announced that Larry R. Smith, Ph.D., Vical's Vice President of Vaccine Research, will participate in a panel discussion at 9:30 a.m. EST on Monday, February 12, at the 2007 Biotechnology Industry Organization (BIO) CEO and Investor Conference in New York. The panel is entitled, "Pandemic Panic: The Current State of Vaccine Research." A webcast will be available through a link in the events page of the Vical web site at www.vical.com. A replay will be available following completion of the live presentation.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the company's focus, collaborative partners, product candidates, and developmental status. Risks and uncertainties include whether any product candidates will be shown to be safe and efficacious in clinical trials, the timing of clinical trials, whether Vical or its collaborative partners will seek or gain approval to market any product candidates, the dependence of the company on its collaborative partners, and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

    Contacts:  Investors:                     Media:
               Alan R. Engbring               Susan Neath
               Vical Incorporated             Porter Novelli Life Sciences
               (858) 646-1127                 (619) 849-6007
               Website:  www.vical.com

SOURCE Vical Incorporated

Investors, Alan R. Engbring of Vical Incorporated, +1-858-646-1127; or Media, Susan
Neath of Porter Novelli Life Sciences, +1-619-849-6007

http://www.vical.com